GlaxoSmithKline (GSK) and Variation Biotechnologies, a subsidiary of VBI Vaccines Inc., recently finalized a partnership in which the company’s researchers will use a
VBI technology called the LPV Platform.
With exclusive use of the LPV Platform, GSK will be able to develop stage therapy. This means that GSK plans to find a new drug with this technology. When the company finds the drug in question, GSK will offer to pay VBI for the rights to develop the drug.
The LPV Platform is focused on providing an alternative to cold chain
storage.
Most drugs on the market are made with natural substances, which is why vaccines and biologics have short shelf lives if they are not stored within the proper low, tight temperature ranges. If the cold chain breaks, the drug is ineffective.
The storage process is expensive, costing the health industry an additional 20 percent to manufacture the drugs. With the new
LPV Platform
technology, VBI and GSK plan to remove the need for cold chain storage, reducing the cost of drugs and improving the accessibility of treatments to people around the world.
VBI has not released many details about the LPV Platform. The technology uses a proprietary formulation to encase the drug’s active component, which will stop a drug from degrading over time even at a much broader temperature spectrum.
